---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038056"
form_type: "8-K"
ticker: null
cik: "0001850079"
company_name: "Telesis Bio Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:34:25.805677+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Telesis Bio Q4 revenue down 26% YoY to $7.0M; net loss widens to $18.3M; BioXp kits hit record $1.0M

## Summary
- Revenue $7.0M in Q4 2023, down 26% YoY from $9.5M; full-year $27.5M flat.
- Net loss $18.3M ($0.61/share) vs $8.1M ($0.28) prior year Q4; includes $11.4M goodwill impairment.
- BioXp kit sales record >$1.0M in Q4, up 59.6% QoQ and 25.9% YoY; mRNA workflow sales grew >300%.
- Operating expense (excl impairment) down 24.4% to $10.8M; headcount reduced from 190 to 138.
- Cash and investments $19.3M at Dec 31, 2023; long-term notes payable $5.3M after $15M repayment.

## SEC filing metadata
- accession: 0000950170-24-038056
- form_type: 8-K
- cik: 0001850079
- company_name: Telesis Bio Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850079/000095017024038056/0000950170-24-038056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850079/000095017024038056/tbio-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038056
- JSON: https://secwatch.observer/filing/0000950170-24-038056.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038056.txt

## Key facts
- Earnings Releases
  Telesis Bio Inc. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 28, 2024, Telesis Bio Inc. (“the Company”) issued a press release (the “Earnings Release”) announcing results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000095017024038056/0000950170-24-038056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.